Hester Biosciences Limited (HESTERBIO) fundamentals
Hester Biosciences Limited is a listed company in Pharmaceuticals & Biotechnology, part of the Healthcare sector, listed on the NSE as HESTERBIO (ISIN INE782E01017). This page carries its reported financials, balance sheet, cash flow, shareholding pattern and valuation ratios.
What Hester Biosciences Limited does
Hester Biosciences Limited is an India-based animal healthcare company. The Company is principally engaged in manufacturing poultry vaccines, large animal vaccines, and trading poultry, large animal, and petcare health products. It operates through three segments: Poultry Healthcare, Animal Healthcare, and Petcare. The Poultry Healthcare vaccines include Gumboro I, Inactivated Chick ND, Inactivated Coryza, Inactivated EDS, Inactivated FC3, Inactivated FC4, Inactivated IB, and Inactivated IBD. The Animal Healthcare vaccines include Goat Pox Vaccine, Live Brucella, PPR Vaccine - Nigerian 75/1, and PPR Vaccine - Sungri/96. Its Petcare products include Cefshot Tazo Injection, Hestacef CV, Hestacef DS, Pawfresh, Synoton, Petsglow, and Vitacoat. The Company also operates diagnostic labs for poultry and provides diagnostic kits for sero-surveillance and mastitis prevention for cattle farms. Its manufacturing facility is located at Meda Adraj Village, Mehsana District, Gujarat.
Valuation and market data
| Last close | ₹2264.90 |
|---|---|
| Market capitalisation | ₹1,927 crore |
| Enterprise value | ₹2,082 crore |
| P/E (TTM) | 33.52 |
| Price to book | 5.24 |
| Price to sales (TTM) | 3.38 |
| Book value per share | ₹432.34 |
| Dividend yield | 48.57% |
| Sector | Healthcare |
| Industry | Pharmaceuticals & Biotechnology |
| Listed since | Fri Mar 13 |
Annual results
| Period | Revenue | Profit before tax | Net profit | EPS |
|---|---|---|---|---|
| Mar 2026 | ₹342 crore | ₹76 crore | ₹57 crore | 67.57 |
| Mar 2025 | ₹315 crore | ₹40 crore | ₹29 crore | 33.89 |
| Mar 2024 | ₹315 crore | ₹32 crore | ₹21 crore | 24.88 |
| Mar 2023 | ₹281 crore | ₹40 crore | ₹28 crore | 31.30 |
Figures are as reported (consolidated), in ₹ crore.
Shareholding pattern
As of Jun 2026:
| Promoters | 53.7% |
|---|---|
| Foreign institutions (FII) | 0.3% |
| Mutual funds | 0.0% |
| Other domestic institutions | 0.0% |
| Retail and others | 46.0% |
More on BreakPoint
FundaX company research covers every listed company with reported financials. BreakPoint Pro adds the BreakPoint iQ score, the screener and the multibagger board.
Data is sourced from exchange filings and vendor feeds and is for research, not investment advice. Figures can be restated by the company after publication.